May 31st, 2006, by Digital Davo | oracea
Collagenex has announced that Oracea has received FDA approval. I doubt many will get excited about this announcement. In effect Collagenex has re-gained the patent it used to have for periostat, albeit with a changed delivery, name and therapeutic target (from gum to skin).
Periostat was 20mg twice a day, used for gum disease ; oracea (great name don’t you think, when targetting rosacea) is 40mg …
May 17th, 2006, by Digital Davo | ocular rosacea, oracea, patents
So called low dose doxycycline, and treating rosacea has had some good research published in recent years. The treatment dose is low enough to not have antibiotic ability, but still give a therapeutic benefit. Tetracyclines have also been used successfully to treat ocular rosacea symptoms. This patent covers the ability to co-treat rosacea and ocular rosacea together.
One would think that such a patent would be …
March 4th, 2006, by Digital Davo | oracea
Another paper readying the rosacea community for the release of Oracea. Collagenex have conducted studies so that they can market Oracea as a safe low-dose doxycyline treatment suitable for the long term treatment of rosacea.
Multicenter, double-blind, randomized, placebo-controlled, parallel-group trial results evaluating the effects of 40 mg doxycycline monohydrate controlled-release capsules in treatment of rosacea, James Del Rosso, DO, University of Nevada, Las Vegas, …
September 19th, 2005, by Digital Davo | doxycycline, oracea, tetracyclines
Some more background about subantimicrobial (sometimes referred to as SD - Subantimicrobial Dosage) doxycycline and rosacea. A dosage of around 50mg per day is enough to see a benefit in rosacea symptoms but also low enough to not affect gut flora or cause other antibiotic related side effects. SD doxycycline can also be take safely for longer periods of time compared to higher doses …
August 2nd, 2005, by Digital Davo | doxycycline, fact sheets, oracea
Periostat (20 mgs doxycycline hyclate) has been helpful to some rosacea sufferers. Originally developed to combat periodontal disease (gum disease), periostat was approved by the FDA in 1998. Recently the FDA approved the introduction of generic periostat equivalents.
Ivax Pharmaceuticals and CorePharma are now free to sell their generic equivalents of Periostat.
Oracea contains doxycycline, the same active ingredient as CollaGenex’s gum disease …
|
|
|
|
|
|
|
|
|